FDA Drafts Rules to Detect Chemicals Leaching into Drugs
Published Date: 12/1/2025
Notice
Summary
The FDA just released a draft guide to help drug makers check for tiny chemicals that might sneak out of packaging or ingredients and into medicines. This new plan affects pharmaceutical companies by giving them clear, risk-based steps to keep medicines safe and high-quality. Comments are open until January 30, 2026, so companies should act fast to share their thoughts and prepare for possible changes that could impact costs and processes.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
ICH Q3E Draft Gives Global Framework
The FDA published a draft ICH Q3E guidance on December 1, 2025 that gives drug makers a holistic, risk-based framework to assess and control extractables and leachables to help ensure patient safety and product quality. The ICH Assembly endorsed the draft in August 2025 and FDA is making it available for public comment as it works toward a final guidance.
New E&L Thresholds and Monographs
The draft guidance discusses thresholds for identifying, quantifying, and reporting extractables and leachables (E&L) and includes draft Class 3 leachable monographs in its supporting documentation. Drug makers will need to review these thresholds and monographs and may need to change testing, reporting, or quality-control processes accordingly.
Public Comment Deadline — Act Now
FDA requests comments on the draft Q3E guidance; comments must be submitted by January 30, 2026 for consideration before work on the final guidance. Companies that want to influence the final text or raise cost concerns should submit comments by that date.
Draft Guidance Is Non-Binding, Final Will Consider Costs
The notice states FDA guidance documents are not legally enforceable and describe the Agency's current thinking; alternative approaches that satisfy statutes/regulations remain permitted. FDA also said it will consider comments on costs or cost savings (relevant to Executive Order 14192) as it develops the final guidance.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.
Previous / Next Documents
Previous: 2025-21701, Combined Notice of Filings
The Federal Energy Regulatory Commission got new filings about natural gas pipeline rates and refunds from companies like Midcontinent Express and Young Gas Storage. These filings could change how much customers pay starting December 1, 2025, and January 1, 2026. If you want to speak up or get involved, you have until December 8, 2025, to file your comments or protests.
Next: 2025-21703, Agency Information Collection Activity: Notice of Disagreement: Appeal to the Board of Veterans' Appeals
The Department of Veterans Affairs is updating the forms veterans use to appeal decisions about their benefits. Veterans who disagree with a VA decision will still use these forms, but the VA wants your feedback on making the process easier and clearer. Comments are open until January 30, 2026, and this update won’t cost veterans extra money or add delays.